image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Scapa - Gain to date: 380%

February 2017

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SCPA
  • Price:
  • 329p
After such a majestic run from 135p to the current 329p in the past two years, the big question is can Scapa’s management keep it going but the signs are still positive, with interim results triggering upgrades for the third time in six months!Helped by strong dollar / weak sterling, interims showed a 13.5% rise in sales to £135.4m (3.7% at constant exchange rates) driving a 27% jump in operating profit (12.4% underlying). Eps rose 28% to 6.4p, while net debt increased from £2.6m to £29m, reflecting the £28m acquisition of EuroMed.Healthcare, which supplies advanced woundcare products and medical tapes like disposable adhesive pads for medical devices, was as usual the key driving force increasin ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X